Captura Biopharma is developing C2E2, an oral chelator designed to bind and eliminate radioactive heavy metals from the body, providing a rapid treatment option for individuals exposed to radiation. This solution addresses the critical need for accessible and effective decontamination methods following nuclear incidents, where traditional intravenous treatments are impractical.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In the event of a nuclear incident, individuals exposed to radiation require rapid decontamination to prevent long-term health effects. Current treatments often involve intravenous administration, which is impractical for large-scale emergencies. This creates a need for easily accessible and rapidly deployable countermeasures.
Solution
Captura Biopharma is developing C2E2, an orally administered chelator designed to bind to and eliminate radioactive heavy metals from the body. C2E2 works by binding radionuclides and harmful metals in the bloodstream, facilitating their quick and efficient expulsion. By trapping and eliminating these particles before they can travel to critical organs, C2E2 aims to protect individuals from the life-threatening damage caused by radiation exposure. The oral administration route makes C2E2 a readily available treatment option for clearing the body of toxic materials faster, offering a quick response to mitigate the hazardous long-term health effects of radiation.
Target Audience
The primary target audience includes individuals, communities, and government agencies requiring a readily available countermeasure for radiation exposure following nuclear incidents or accidents.
Features
- Oral formulation for easy administration in emergency situations
- Chelator designed to bind to radioactive heavy metals
- Facilitates rapid elimination of harmful elements through the bloodstream
- Protects critical organs from radiation damage